Several committees have been established to provide advice to the Chief Executive Officer (CEO) on relevant matters related to organ and tissue donation and transplantation in Australia.
The Organ and Tissue Authority (OTA) has a three-tier committee structure:
- Program governance and advice, comprising the Advisory Council and Jurisdictional Advisory Group.
- Committees established by the CEO to provide sector specific advice and liaison, comprising of the Clinical Governance Committee, Charter Signatories and Transplant Liaison Reference Group.
- Purpose-specific Working Groups such as the Data and Audit Working Group established by the CEO from time to time and disbanded once the assigned task is accomplished.
Following is a list of the OTA's committees, their membership and their functions.
The Audit Committee
The Audit Committee, a central governance element for the Organ and Tissue Authority, was established by the OTA’s Chief Executive Officer, as the accountable authority, in accordance with section 45 of the Performance, Governance and Public Accountability Act 2013.
The role of the Audit Committee is to provide independent assurance and assistance to the Chief Executive Officer to meet the OTA’s responsibilities under the PGPA Act, particularly in relation to risk control, compliance frameworks and external accountabilities.
The Audit Committee comprises two independent external members (Chair Mr Peter Hoefer, Deputy Chair Ms Glenys Roper) and one internal member. The Chief Executive Officer, Chief Financial Officer and representatives from the Australian National Audit Office and Internal Audit staff are invited to attend each meeting.
Jurisdictional Advisory Group
The Jurisdictional Advisory Group is the premier governance committee for the DonateLife Network. The group is chaired by the CEO and comprises State Medical Directors, the National Medical Director and jurisdictional health department representatives. The group considers and makes recommendations to the CEO in respect of strategic priorities, clinical and data governance, planning and leadership of the DonateLife Network, and implementation of the Australian Government's national reform programme on organ and tissue donation.
Jurisdictional Advisory Group Communiqués
2016 Jurisdictional Advisory Group Communiqués
2015 Jurisdictional Advisory Group Communiqués
2014 Jurisdictional Advisory Group Communiqués
2013 Jurisdictional Advisory Group Communiqués
2012 SMD Communiques
2011 SMD Communiques
2010 SMD Communiques
Clinical Governance Committee
The peak clinical committee for the DonateLife Network is the Clinical Governance Committee which pursues specific clinical issues relevant to the DonateLife Network. The committee is chaired by the National Medical Director and comprises the Chief Executive Officer, State and Territory Medical Directors and Agency/ Clinical/ Operational Managers from each State and Territory. The committee makes recommendations related to the clinical aspects of the national reform programme for consideration by the Jurisdictional Advisory Group.
Transplant Liaison Reference Group
The Transplant Liaison Reference Group provides advice to the CEO and facilitates engagement with the transplant sector on transplantation issues relevant to the national reform programme. Membership comprises the CEO, the National Medical Director and representatives from the: Transplantation Society of Australia and New Zealand, Australasian Transplant Coordinators Association; Transplant Australia; Transplant Nurses Association, Australia and New Zealand Organ Donation Registry; and Australia and New Zealand Intensive Care Society.
The main mechanism for engagement with the non-government sector and the community is the group of signatories to the DonateLife National Communications Framework and Charter. This is a key mechanism to ensure that Charter Signatories are provided with the necessary information to take a nationally consistent and coordinated approach to communicating with the community.
The OTA has a large range of stakeholders including: consumer groups; professional and peak bodies involved in donation and transplantation; Australian Government agencies and authorities; and state and territory health departments and hospitals.